

To,

Date: 31.07.2023

BSE Limited  
P. J. Towers, Dalal Street  
Mumbai – 400001  
Dear Sir,

**Sub:** Outcome of Board Meeting held on 31.07.2023

**Ref:** Hindustan Bio Sciences Limited (Scrip Code: 532041)

With reference to the subject cited, this is to inform the exchange that at the Board Meeting of M/s. Hindustan Bio Sciences Limited held on Monday, 31.07.2023 at 02:00 P.M. at the registered office of the company at Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad-500034, Telangana, considered and approved the following items of business:


- 1 The Board approved the Un-audited financial results of the company for the quarter ended 30-06-2023 placed before the board for their consideration
- 2 The Board has approved the notice of 31<sup>st</sup> Annual General Meeting; Directors report etc. for the FY ended on 31-03-2023 and decided to conduct the AGM at the registered office of the company at 10:00 A.M. on 30<sup>th</sup> September, 2023.
- 3 Secretarial Audit Report submitted by Mr. VBSS Prasad, Practicing Company Secretary was considered and noted by the Board for the Financial Year 31-03-2023.
- 4 Mr. VBSS Prasad, Practicing Company Secretary (C.P.No.4605), has been appointed as a scrutinizer for conducting E-voting in the ensuing Annual General Meeting.
- 5 The Re-appointment of Mr. Venkata Rama Mohan Raju Jampana (DIN No: 00060800) w.e.f. 29<sup>th</sup> February 2024 was approved by the board and the same will be placed before the shareholders in the ensuing AGM for their approval.
- 6 The board has reviewed the Limited Review Report for quarter ended 30.06.2023 and taken a note of the same.

The meeting concluded at 2.45 PM

This is for your information and records.

Thanking you.

For and on behalf of  
Hindustan Bio Sciences Limited

  
Venkata Rama Mohan Raju Jampana  
Managing Director

(DIN: 00060800)



**HINDUSTAN BIOSCIENCES LTD.**

#31, Sagar Society, Road No. 2,  
Banjara Hills, Hyderabad - 500 034, INDIA.

+91 40 23555161 / 23555181  
pharma.hindustanbio@gmail.com

www.hindustan.bio

CIN : I26942TG1991PLC012544

**HINDUSTAN BIO SCIENCES LIMITED**  
 Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034  
 Phone No. 23555161, Fax 40205171  
**STATEMENT OF UN AUDITED RESULTS FOR THE QUARTER ENDED 30th JUNE,2023**

Rs. In Lakhs

Sl. No.	Particulars	Quarter ended		Year ended	
		30.06.2023 (unaudited)	31.03.2023 (Audited)	30.06.2022 (unaudited)	31.03.2023 (Audited)
1	Income from Operations				
	(a) Revenue from operations	-	33.28	27.14	92.23
	(b) Other Income	-	-	-	-
	Total Revenue ( 1)	-	33.28	27.14	92.23
2	Expenses				
	(a) cost of material consumed	-	-	-	-
	(b) Purchases of Stock -in-trade	-	20.45	18.29	57.03
	( c) Changes in Inventories of finished goods,Stock - in-Trade and Work-in-Progress	-	-	-	-
	(d) Employee Benefit Expenses	5.26	5.91	5.93	23.92
	(e) Finance Costs	0.11	0.21	0.03	0.41
	(f) Selling Expenses	-	0.63	0.33	1.53
	(g) Depreciation and amortisation Expenses	0.13	0.25	0.10	0.57
	(h) Other Expenses	6.73	4.39	4.97	12.57
	Total Expenses( 2 )	12.23	31.84	29.65	96.03
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	(12.23)	1.44	(2.51)	(3.80)
4	Exceptional items	-	-	-	-
5	Profit/(Loss) before tax(3 -4)	(12.23)	1.44	(2.51)	(3.80)
6	Tax Expenses				
	(a) Current Tax	-	-	-	-
	(b) Previous Taxes	-	-	-	-
	(b) Deferred Tax	-	0.25	-	0.25
7	Profit /(Loss) for the period from continuing operations(5-6)	(12.23)	1.19	(2.51)	(4.05)
8	Profit /(Loss) from discontinued operations	-	-	-	-
9	Tax Expense of discontinued operations	-	-	-	-
10	Profit /Loss from Discontinued operations after tax(8-9)	-	-	-	-
11	Profit/(Loss) for the period(7+10)	(12.23)	1.19	(2.51)	(4.05)
12	Other Comprehensive Income				
	A (1) Items that will not be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will not be re- classified to profit or loss	-	-	-	-
	B (1) Items that will be reclassified to profit or loss	-	-	-	-
	(2) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
13	Total Comprehensive Income for the period (11+12) (comprising Profit (Loss) and other comprehensive income for the period	(12.23)	1.19	(2.51)	(4.05)
14	Paid up Equity Capital(Face value of Rs. 10/- each) upto 05.01.2023			1,025.08	
	Paid up Equity Capital(Face value of Rs. 2/- each) from 06.01.2023	205.02	205.02		205.02
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				
16	Earnings per equity share for continuing operations				
	(A) Basic	(0.12)	0.01	(0.02)	(0.04)
	(B) Diluted	(0.12)	0.01	(0.02)	(0.04)
17	Earnings per equity share for discontinuing operations				
	(A) Basic	-	-	-	-
	(B) Diluted	-	-	-	-
18	Earnings per equity share(for discontinuing & continuing operations				
	(A) Basic	(0.12)	0.01	(0.02)	(0.04)
	(B) Diluted	(0.12)	0.01	(0.02)	(0.04)

**Notes:**

- 1 The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.07.2023.
- 2 The previous Year figures have been regrouped wherever necessary

Place: Hyderabad  
 Date : 31.07.2023

for Hindustan Bio Sciences Limited

J.V.R.Mohan Raju  
 Managing Director  
 (DIN:00060800)





INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE  
FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF  
M/S HINDUSTAN BIO SCIENCES LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/S. HINDUSTAN BIO SCIENCES LIMITED (the "Company"), for the quarter and period ended June 30, 2023, being prepared by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 as amended.

The preparation of this statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('IND AS 34'), prescribed under section 133 of the companies act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India is the responsibility of the company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s VASG & Associates  
Chartered Accountants  
FRN:006070S



A Viswanatha Rao  
Partner  
M no:029597

UDIN: 23029597BGT FUI 6032  
Date: 31.7.2023